Trump Budget Headlines Include Generic Exclusivity Changes; Medicare/Medicaid Savings

On February 8, 2018, Bloomberg Politics reported HHS Secretary Alex Azar’s announcement that “…he plans to take up the president’s promises to do something about pharmaceutical prices, targeting some of the U.S.’s costliest drugs with proposals to reduce patients’ out-of-pocket spending.

‘The president is firmly committed in this space,’ Health and Human Services Secretary Alex Azar said in a briefing with reporters Thursday. ‘I am now less than two weeks on the job and have been working a great deal, let’s just say, on these issues already. We do think drug prices are too high.’

Azar laid out several ideas that will appear in Trump’s budget proposal when it’s released Monday. Many would have to be legislated by Congress, which typically ignores presidents’ budgets and lays out its own framework.”

Click here for the full story, or here for help with your next Type B or C meeting with FDA.

On February 12, 2018, Trump’s Budget Proposal was released. Here are a sampling of the headlines that followed:

Trump FY 2019 Budget Calls for 180-Day Exclusivity Changes for Generic Drugs
RAPS Regulatory Focus, Monday, February 12, 2018

TRUMP’S BUDGET PROPOSAL TO DEVOTE $13 BILLION FOR OPIOID CRISIS RESPONSE
Newsweek, Monday, February 12, 2018

White House Targets Generic Exclusivity to Lower Drug Prices
Bloomberg BNA, Tuesday, February 13, 2018

TRUMP’S BUDGET TARGETS HEALTH PROGRAMS
POLITICO, Tuesday, February 13, 2018

FDA gives thumbs up to Trump’s budget proposal
The Pharma Letter, February 14, 2018

print